» Articles » PMID: 26457910

Process of Allogeneic Hematopoietic Cell Transplantation Decision Making for Older Adults

Overview
Specialty General Surgery
Date 2015 Oct 13
PMID 26457910
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) may be the only curative option for some older adults with hematologic malignancies, and its associated risks of significant morbidity and mortality warrant a clear, informed decision-making process. As older adults have not been transplanted routinely until recent years, younger people have been the prototypical group around whom the current process has developed. Yet, this process is applied to older adults who have different considerations than younger patients when making their transplant decision. Older adults do not have the open-ended lives of younger patients and are entitled to consider how to spend their remaining time. They also possess maturity and experience, and with proper knowledge, they can make informed choices rather than moving forward in the transplant process unaware. Notably, older patients face similar problems with the informed decision-making process in nephrology. Strategies such as providing education about alloHCT gradually and repeatedly during induction, presenting recent knowledge from the literature in plain language, and utilizing a team approach to patient education may help older adults make the best decision about transplant in light of their situation and values. Understanding when and how older adults decide on alloHCT is an important first step to further exploring this problem.

Citing Articles

Communication Strategies of Transplant Hematologists in High-Risk Decision-Making Conversations.

Rodenbach R, Thordardottir T, Brauer M, Hall A, Ward E, Smith C JCO Oncol Pract. 2024; 20(4):538-548.

PMID: 38241601 PMC: 11590740. DOI: 10.1200/OP.23.00574.


Investigating and Supporting Patient and Caregiver Sensemaking in Complex Medical Decisions Using Participatory Design.

Fadem S MDM Policy Pract. 2023; 8(1):23814683231164988.

PMID: 37077898 PMC: 10107376. DOI: 10.1177/23814683231164988.


Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up.

Kim K, Kim T, Novitzky-Basso I, Lee H, Yoo Y, Ahn J Haematologica. 2023; 108(7):1817-1826.

PMID: 36727396 PMC: 10316278. DOI: 10.3324/haematol.2022.281806.


Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care.

Olin R Hematology Am Soc Hematol Educ Program. 2019; 2019(1):63-70.

PMID: 31808886 PMC: 6913447. DOI: 10.1182/hematology.2019001300.


Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang H, Othus M, Sun Z, Major B Leukemia. 2019; 33(11):2599-2609.

PMID: 31073153 PMC: 6842042. DOI: 10.1038/s41375-019-0477-x.


References
1.
Bertoli S, Berard E, Huguet F, Huynh A, Tavitian S, Vergez F . Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013; 121(14):2618-26. DOI: 10.1182/blood-2012-09-454553. View

2.
Elsawy B, Higgins K . The geriatric assessment. Am Fam Physician. 2011; 83(1):48-56. View

3.
Pidala J, Kurland B, Chai X, Majhail N, Weisdorf D, Pavletic S . Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011; 117(17):4651-7. PMC: 3099579. DOI: 10.1182/blood-2010-11-319509. View

4.
Gokbuget N . How I treat older patients with ALL. Blood. 2013; 122(8):1366-75. DOI: 10.1182/blood-2012-07-379016. View

5.
Ustun C, Lazarus H, Weisdorf D . To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century. Bone Marrow Transplant. 2013; 48(12):1497-505. DOI: 10.1038/bmt.2013.67. View